DDInter1001 DDInter1376
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ixabepilone {u} (Compound) treats {v} (Disease) breast cancer
Ixabepilone {u} (Compound) binds {v} (Gene) TUBB3
Ixabepilone {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Ixabepilone {u} (Compound) causes {v} (Side Effect) Dehydration
Ixabepilone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capecitabine
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Ixabepilone (Compound) treats breast cancer (Disease)
Ixabepilone (Compound) binds TUBB3 (Gene)
Ixabepilone (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Ixabepilone (Compound) causes Dehydration (Side Effect)
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Clozapine
Ixabepilone may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated